Genmab — April 2019

[Solsen]

Så køber vi flere. Mange gør stærk

[E_L]

so most of them were management and sold today, about 2/3

[Solsen]

I dont se that they are sold ?

[Bulder]

Neither do I. Danske hardly sold any - only 8k

[peter12]

If they believe in Maia they will wait ?

[E_L]

my mistake, i thought the link from bibob were sales, but it was Subscription, sry.

[Bulder]

Well, management was 102,650 shares. Maybe they'll keep them.

[E_L]

@peter12 some may not have enough cash to wait ; they will need to pay for the shares and for taxes , so they may be forced to sell to fund that

[bibob]

New questions about the tradeoffs in ‘accelerated’ cancer drug studies

Cancer clinical trials that use surrogate endpoints end up saving relatively little time, a new study finds.

OHSU News (news.ohsu.edu)

[Bulder]

Ikke ringe, hvis man kunne købe 45k aktier til 80 kr stykket.

[bibob]

Genmab igen på Børsen. https://borsen.dk/nyheder/avisen/artikel/11/222471/artikel.html?utm_source=forside&utm_campaign=nyhed_01

[JKY_VH]

tak for den bibob;-)

[Sukkeralf]

Hvad står der i den bibob?

[bibob]

Har desværre ikke adgang, men flot overskrift.

[Sukkeralf]

Hvad står der JKY?

[Sukkeralf]

(tom indlæg)

[bibob]

Men JvdW har det jo med at komme med store overskrifter. Hele verden er jo en ordentlig mundfuld.

[Bulder]

Det må være enten cd3xcd20 eller duohex cd37.

[bibob]

Det ville da være fint at få fokus flyttet over på andre drugs.

[JKY_VH]

"Der er tale om Genmabs lægemiddelkandidat, der indtil videre hedder Duobody-CD3xCD20 og er rettet mod B-celledefekter, blandt andet lymfekræft. Den schweiziske gigant Roche og den amerikanske biotekvirksomhed Regeneron har lignende antistoffer under udvikling."